Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with preoperative chemoradiotherapy for rectal adenocarcinoma
ISRCTN11319909Phase 2Completed
- Sponsor
- University College London
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of cetuximab in rectal adenocarcinoma and rectal cancer, sponsored by University College London. Primary endpoints: Acute toxicity and Compliance with planned radiotherapy. Started Dec 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on ISRCTN11319909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11319909.